Skip to main content

Frankincense, Indian

Scientific Name(s): Boswellia serrata Roxb.
Common Name(s): Dhup, Indian frankincense tree, Indian olibanum, Salai guggal

Medically reviewed by Last updated on Aug 16, 2022.

Clinical Overview


The oleoresin gum from B. serrata has traditionally been used for its anti-inflammatory effects in conditions such as asthma, osteoarthritis, rheumatoid arthritis, colitis, and irritable bowel syndrome. It has also been used for the management of diabetes, urinary conditions, dermatological ailments, and renal impairment. Boswellic acids have demonstrated immunomodulatory, antiproliferative, cytotoxic, and antimicrobial effects; however, there are no adequate clinical trials to support any of the uses.


Administration with high-fat foods may enhance plasma levels of B. serrata. Asthma: 300 to 400 mg of an extract (containing 60% boswellic acids) 3 times daily. In one trial, 300 mg 3 times daily of powdered gum resin capsules (S-Compound), or 400 mg 3 times daily of an extract (standardized to 37.5% boswellic acids per dose) was used. Inflammatory conditions: 300 to 400 mg of a B. serrata extract (containing 60% boswellic acids) 3 times daily was used in a clinical trial of patients with knee osteoarthritis. Two capsules of Articulin-F (contains B. serrata, Withania somnifera, Curcuma longa, zinc complex) 3 times daily; or supplementation with Casperome (150 mg of boswellic acids) 3 times daily has been used for inflammatory conditions such as osteoarthritis and rheumatoid arthritis. Ulcerative colitis: 350 to 400 mg 3 times daily.


Hypersensitivity to B. serrata.


Avoid use. Information regarding safety and efficacy in pregnancy and lactation is lacking.


Substrates of cytochrome P450 (CYP-450) 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4: Upon liquid chromatography mass spectrometry analysis, frankincense derived from B. serrata demonstrated inhibition of CYP1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. Therefore, caution is warranted when using B. serrata with medications that are substrates for these isoenzymes. Substrates for P-glycoprotein (P-gp): Data suggest that B. serrata extract and the major boswellic acids may be potent inhibitors of P-gp via modulation of transport activity at the GI level, but not at the blood-brain barrier. Therefore, medications that depend on P-gp transport across the GI membrane may be impacted with coadministration of B. serrata. Warfarin: According to 2 case reports, coadministration of warfarin and B. serrata may increase international normalized ratio (INR) levels. The interaction may be attributed to inhibition of lipoxygenase and interference with COX-1 by B. serrata. In addition, B. serrata might inhibit CYP2C19, 3A4, and 2C9, which are involved in the metabolism of warfarin. Use of B. serrata in patients receiving warfarin is not recommended.

Adverse Reactions

Diarrhea, abdominal pain, and nausea have been reported.


No data.

Scientific Family

  • Burseraceae


The Burseraceae family of trees and shrubs consists of 18 genera and more than 540 species that grow mostly in tropical regions of India (B. serrata), North Africa (Boswellia carteri, Boswellia frereana), and the Arabian Peninsula (Boswellia sacra). Most species contain resin ducts in the bark, which yield the products myrrh and frankincense.1, 2 B. serrata is a branching tree that grows on dry, hilly areas throughout most of India and can reach up to 3.7 m in height.3 When the bark is cut, the aromatic balsam, or gum resin, oozes out and is used for medicinal purposes.4 The semi-solid resin is typically harvested each summer and fall and is collected in bamboo baskets, where it remains for approximately 1 month, during which the fluid is drained out. The residue, which is semi-solid to solid, is the part of the gum resin that slowly hardens and is eventually broken into smaller pieces. The tree can produce a quality product for a period of 3 years, after which time the tree should be allowed to rest before being harvested again.5 The oleoresin contains oils, terpenoids, and gum.6


The Indian frankincense tree is thought to be related to the tree in the Bible that brought forth the frankincense given by the wise men as a gift to the baby Jesus. In Ayurvedic medicine in India, different parts of the tree have been used for asthma, rheumatism, dysentery, skin ailments, ulcers, blood purification, bronchial conditions, and wound treatment.4 B. serrata is discussed in Ayurvedic texts using the name "Gajabhakshya," meaning it was consumed by elephants.7 Frankincense is also used to perfume clothes, hair, and rooms. It was used in ancient Egypt as an ingredient in embalming liquids for mummification. It has historically been burned in religious and/or spiritual ceremonies and is said to produce a psychoactive substance.8 In 2002, the European Medicine Agency classified the gum resin extract of B. serrata as an orphan drug.9


B. serrata contains oils, terpenoids, sugars, and volatile oils. Four pentacyclic triterpenes are also present: beta-boswellic acid, acetyl-beta-boswellic acid, 11-keto-beta-boswellic acid, and acetyl-11-keto-beta-boswellic acid.3, 6, 10, 11

Uses and Pharmacology

Anticancer effects

Animal and in vitro data

In an in vitro study, acetyl-keto-beta-boswellic acid and keto-beta-boswellic acid exerted antiproliferative and apoptotic effects in human HT-29 colon cancer cells.12 Similarly, apoptotic effects of boswellic acid acetate were observed in myeloid leukemia cells.13 Cytotoxic effects were noted with acetyl-11-keto-beta-boswellic acid in glioblastoma and leukemia cell lines.14

In a murine model, acetyl-11-keto-beta-boswellic acid 50 to 200 mg/kg given orally inhibited the growth of colorectal cancer cells in a dose-dependent manner, with a subsequent reduction in tumor volume; it was also associated with a reduction in ascites and in metastases to the liver, lungs, and spleen.15

An extract of B. serrata caused a loss of viability and inhibited proliferation of 5 leukemia and 2 brain tumor cell lines in a dose-dependent manner.16

Clinical data

In a study of patients with primary or secondary malignant cerebral tumors, a greater than 75% reduction in cerebral edema was observed in 60% of patients receiving radiotherapy plus B. serrata 4,200 mg/day, compared with 26% of patients receiving radiotherapy alone (P=0.023).17

In a case study of a 39-year-old woman with breast cancer brain metastases, a computed tomography scan showed complete disappearance of brain metastases following administration of B. serrata 2,400 mg/day for 10 weeks. The patient continued this regimen for 4 years with no new signs of brain involvement; however, she did develop skeletal metastases.18

In a study of 19 children and adolescents with intracranial tumors, palliative treatment with H15, a phytotherapeutic agent derived from the gum resin of B. serrata, resulted in various improvements in overall health status, neurological symptoms (ataxia, paresis), and muscle strength; one cachectic patient achieved weight gain.19

In a study of 12 patients with brain tumors and associated progressive edema, H15 1,200 mg 3 times daily reduced edema in 2 of 7 patients with glioblastoma and in 3 of 5 patients with leukoencephalopathy. In general, the maximum treatment response was noted within 4 weeks of initiation, and no further reduction was noted with continued treatment.20

Antidiabetic effects

Animal and in vitro data

In a study of diabetic rats, administration of B. serrata (a dose of 200 mg/kg was most effective) significantly reduced blood glucose and hemoglobin A1c levels after 17 days (P≤0.01).21 A B. serrata extract also greatly attenuated effects in a mouse model of induced diabetes.22

Clinical data

In a study of 56 patients with diabetes, B. serrata 250 mg twice daily for 8 weeks did not impact glucose or lipid levels compared with placebo.23 Further investigation of the effects of B. serrata extract on late-onset autoimmune diabetes is needed; one case report noted both clinical improvement and decreased IA2 antibodies in a patient treated with a B. serrata extract.24

Anti-inflammatory effects

In vitro, boswellic acids are specific inhibitors of 5-lipoxygenase (5-LO), the key enzyme of leukotriene biosynthesis. Leukotrienes are biochemicals in the body that maintain inflammation. Of the 4 boswellic acids, acetyl-11-keto-beta-boswellic acid is the most potent 5-LO inhibitor11 and appears to act directly on 5-LO at a selective site for pentacyclic triterpenes.25 Boswellic acids have traditionally been used in treating inflammatory conditions such as arthritis, tendinopathy, and bursitis.4, 10

Animal and in vitro data

Anti-inflammatory activity of B. serrata has been studied in animals.10 The plant extract displays marked anti-inflammatory action and antiarthritic activity in rats, with no significant adverse reactions.26 In one report evaluating boswellic acid inhibition of leukotriene synthesis (via 5-LO), no effect on 12-lipoxygenase, cyclooxygenase, or the peroxidation of arachidonic acid by iron and ascorbate was observed, suggesting that boswellic acids are specific, nonredox inhibitors of leukotriene synthesis.27 Similar results were found in rat peritoneal neutrophils.28, 29

B. serrata was ineffective in the prevention of weight loss or mucosal damage caused by colitis in a study of mice. No improvements in mortality or histology of the colon were noted.30

In a study of rats, boswellic acids demonstrated antiulcerogenic effects in various models of ulceration.31 In addition, B. serrata exerted anti-inflammatory and antioxidant effects in an experimental model of acute colitis in rats.32

Clinical data

GI conditions

B. serrata appears to have benefit in ulcerative colitis due to its ability to inhibit 5-LO. In a clinical trial, patients given B. serrata gum resin preparation (350 mg 3 times daily) for 6 weeks experienced improvement in parameters of ulcerative colitis (eg, stool properties, histopathology, rectal biopsies, blood work) compared with patients receiving sulfasalazine (1 g 3 times daily). Remission was 82% with the resin and 75% with sulfasalazine.33 In a study of patients with ulcerative colitis who were in a minimally symptomatic remission phase, administration of 250 mg/day of Casperome, a lecithin-based delivery system for B. serrata designed to improve bioavailability, had a beneficial effect on parameters of intestinal pain (ie, evident and occult blood in stools, bowel movements, cramping, diarrhea, malaise, anemia, rectal involvement, white blood cell count, need for additional drugs or medical attention).34

A meta-analysis identified 7 placebo-controlled clinical trials that evaluated the efficacy and tolerability of herbal medicines in inflammatory bowel disease. Based on 2 studies (N=113) evaluating B. serrata in patients with Crohn disease or collagenous colitis, a significant result was identified for induction of clinical remission (relative risk, 2.34).35 However, a relevant systematic review of randomized trials found B. serrata to be ineffective for the treatment of collagenous colitis; however, the authors note that the studies reviewed may have been underpowered to detect a difference.36 One trial reviewed (Madisch et al) included 31 patients, 26 of whom were included in the per-protocol analysis. After 6 weeks of receiving oral B. Serrata 400 mg 3 times daily, more patients in the treatment group were in remission compared with those in the placebo group. The difference was significant in the per-protocol group compared with placebo (P=0.04) but not in the intention-to-treat group (P=0.25), indicating a possible flaw in the study design.37, 38

In a randomized controlled trial comparing the efficacy and safety of B. serrata extract (H15) with mesalazine in patients with active Crohn disease, B. serrata was found to be non-inferior to mesalazine.39 In another trial, B. serrata given for 1 year was assessed for use in maintaining remission in patients with Crohn disease. The study was halted early due to a high dropout rate as well as low patient recruitment. The data analyzed did not reveal a difference between treatment and placebo.40

In a study of 30 patients with chronic colitis, patients received either B. serrata 300 mg 3 times daily or sulfasalazine 1 g 3 times daily for 6 weeks. Of the patients receiving B. serrata, 90% reported an improvement in at least one parameter such as stool properties, histopathology, or microscopy, and 70% went into remission. With sulfasalazine, 60% demonstrated improvement and 40% went into remission.41


In a randomized, double-blind clinical study of high school females with gingivitis, B. serrata extract exerted anti-inflammatory effects.42

Osteoarthritis and other pain

In a double-blind, randomized, crossover trial of healthy adult male volunteers (N=12), pain threshold and tolerance were significantly increased with administration of a single oral dose of B. serrata 125 mg (2 capsules) compared with placebo. Using a mechanical pain model, subjects experienced a significant increase from baseline in mean pain threshold force and time at 2 hours and 3 hours after drug administration compared to placebo (P<0.05); mean pain threshold force and time with B. serrata were also statistically significant at 3 hours compared to baseline (P<0.05). Additionally, mean pain tolerance force and time were significantly increased at all 3 time points (ie, 1, 2, and 3 hours after drug administration) compared with baseline (P<0.05). Mean percentage change from baseline in pain tolerance force and time was also significantly increased at all time points compared with placebo (P≤0.01).43

In a Cochrane review of combined data from 2 high-quality studies in a small number of patients (N=85), a B. serrata 100 mg/day extract administered for 90 days improved symptoms of osteoarthritis. Specifically, B. serrata reduced the mean visual analog scale (VAS) score by 17 points compared with placebo, with a number needed to treat for an additional beneficial outcome of 2. Patients receiving B. serrata reported improvements in physical function (ie, 8-point improvement) compared with placebo.44

In a randomized, double-blind, placebo-controlled crossover study of 42 osteoarthritic patients, B. serrata in an herbomineral combination was compared with placebo. B. serrata decreased pain and disability scores, but radiological assessment showed no change.45 Similarly, in a crossover study of 30 patients with osteoarthritis of the knee, B. serrata 1 g/day for 8 weeks improved knee pain, knee flexion, walking distance, and swelling.46 After 120 days of treatment with a standardized B. serrata extract (Boswellin, equivalent to 87.3 mg of total beta-boswellic acids twice daily), multiple outcomes including pain, ability to walk, quality of life, radiological improvements and the inflammatory biomarker high-sensitivity C-reactive protein were significantly improved compared to placebo in patients with osteoarthritis of the knee in a double-blind, randomized controlled trial.81 When compared with valdecoxib, patients receiving B. serrata extract for osteoarthritis of the knee experienced improvements in pain, stiffness, and difficulty performing activities after 2 months of treatment; these effects persisted until 1 month after discontinuation. While valdecoxib was also successful in improving these parameters after 1 month of therapy, its effects persisted only as long as treatment was continued.47

Novel products produced from B. serrata have been tested in clinical studies. Aflapin, which is derived from the gum resin of B. serrata, improved pain and physical function scores in patients with osteoarthritis of the knee when dosed at 100 mg/day for 30 days.48 Similar results were noted in patients with osteoarthritis of the knee receiving 5-Loxin (a B. serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid) 250 to 500 mg/day for 90 days, with improvement noted as early as 7 days after initiation of treatment.49 In a study of 52 male rugby patients with knee pain without osteoarthritis, Casperome (derived from the extract of B. serrata) dosed at 500 mg/day for 5 days followed by 250 mg/day for 23 days improved local pain on effort, pain-free walking distance, joint effusion, structural damage, thermal imaging, and VAS pain scores.50

An older review of the literature suggests potential benefit of the gum resin of B. serrata in the treatment of rheumatoid arthritis.51 In a small study of 4 patients with chronic cluster headaches receiving B. serrata, long-lasting analgesic effects (mean, 15 months) were noted in 3 patients, and transient analgesic effects (mean, 6 months) were noted in 1 patient.52

Antimicrobial effects

Animal and in vitro data

Acetyl-11-keto-beta-boswellic acid exerted antibacterial effects against Staphylococcus aureus in an in vitro model.53

In an in vitro study, B. serrata was found to exert antiprotozoal activity against Trypanosoma brucei and Plasmodium falciparum.54

In a study evaluating various commercially available essential oils for antimicrobial activity, B. serrata essential oil exerted antimicrobial activity against Trichophyton spp. It was also found to exert a synergistic effect with azoles against azole-resistant Candida albicans. Thus, B. serrata may be useful in the treatment of skin, scalp, and nail infections.55

Asthmatic effects

Boswellic acids may be beneficial in the management of asthma due to inhibition of leukotriene biosynthesis through 5-LO inhibition.56

Clinical data

A systematic review and meta-analysis conducted in 2010 evaluated several complementary alternative products, including boswellic acids, for the management of asthma. Given the small sample sizes, short durations of study, and poor methodologies, among other limitations, it is challenging to make a recommendation regarding use of boswellic acids for the management of asthma. Individual studies determined differences in peak expiratory flow rate and forced vital capacity.57

In a small double-blind, placebo-controlled clinical study, administration of 300 mg of the gum resin of B. serrata 3 times daily for 6 weeks improved physical symptoms such as dyspnea and rhonchi, number of attacks, and spirometry measures in 70% of patients, compared with 27% of those receiving placebo.58

Dermatological effects

Clinical data

In a randomized, double-blind, placebo-controlled study, the effects of a cream containing boswellic acids 0.5% were assessed in 15 women with photoaged skin. Patients were given 2 tubes, one containing boswellic acids and the other containing simply an emollient. Patients were instructed to apply 1 cream to each half of the face once daily for 30 days. The application of boswellic acid cream was associated with improvements in Dover's global score for photoaging, tactile roughness, fine lines, and elasticity, as well as with a reduction in sebum excretion.59, 60

A randomized, placebo-controlled, parallel-group study in 114 women undergoing adjuvant radiotherapy following surgery for breast cancer evaluated the safety and efficacy of a cream containing boswellic acids (Bosexil) compared with base cream for the prevention of radiation-induced dermatological effects. The cream was applied twice daily on radiation days immediately after radiation. Application of the boswellic acid–containing cream was associated with a reduced grade of erythema, with visual intensity rated as "intense" in a larger portion of those receiving base cream (49%) compared with those receiving boswellic acid–containing cream (22%; P=0.009). In addition, the use of topical steroids was reduced with use of boswellic acid–containing cream.61

In a randomized, double-blind, placebo-controlled study in patients with psoriasis, administration of Bosexil twice daily for 30 days improved scales in 70% and erythema in 50% of cases. In patients with eczema, 60% reported improvements in itching, and 60% reported improvements in erythema.62

Immunomodulatory activity

Animal and in vitro data

Mast cell stabilizing activity was demonstrated with an extract of gum resin of B. serrata in a murine model.63 In an immunological study, boswellic acids were shown to possess anticomplementary activity via C3-convertase inhibition.64 C3-convertase is involved in the production of anaphylatoxin.65

Renal effects

Animal data

In a murine model, B. serrata partially protected the kidneys in both acute and chronic renal failure. Arabic gum and ginger had more promising results compared with B. serrata.66

Clinical data

In a study of 16 patients with chronic kidney disease not on dialysis, the combination of B. serrata and C. longa administered for 8 weeks improved levels of interleukin-6; however, no differences were noted in other markers, such as tumor necrosis factor-alpha, glutathione peroxidase, and serum C-reactive protein.67

Urinary effects

B. serrata may be useful for the treatment of stress incontinence because of its astringent properties and ability to tone the muscles.68

Clinical data

In a prospective, single-blind, placebo-controlled, randomized clinical trial of women of reproductive age with stress incontinence, the combination of B. serrata and Cyperus scariosus (1 g of each powder twice daily for 8 weeks) in addition to pelvic floor muscle training was associated with a 23% greater improvement in alleviation of stress incontinence compared with pelvic floor muscle training alone (60% cure rate vs 36.67%; P=0.035).68

In a randomized study of men with chronic prostatitis, antibiotics plus Proxelan suppositories (an herbal blend containing Boswellia) improved patient symptoms but did not change microbiological results compared with antibiotics alone. The exact species of Boswellia used is unclear.69

Other uses

In an in vitro study, beta-boswellic acid exerted protective effects on blood stasis–induced endothelial function by increasing phosphorylation of enzyme nitric oxide synthase.70

In a fully allogenic mouse heart transplantation model, boswellic acid resulted in prolongation of graft survival time.71


Administration with high-fat foods may enhance plasma levels of B. serrata.72


300 to 400 mg of an extract (containing 60% boswellic acids) 3 times daily.3 In one trial, 300 mg 3 times daily of powdered gum resin capsules (S-Compound), or 400 mg 3 times daily of an extract (standardized to 37.5% boswellic acids per dose) was used.8

Inflammatory conditions

300 to 400 mg of a B. serrata extract (containing 60% boswellic acids) 3 times daily was used in a clinical trial of patients with knee osteoarthritis.3

Two capsules of Articulin-F (contains B. serrata, W. somnifera, C. longa, zinc complex) 3 times daily8; or supplementation with Casperome (150 mg of boswellic acids) 3 times daily has been used for inflammatory conditions such as osteoarthritis and rheumatoid arthritis.40

Ulcerative colitis

350 to 400 mg 3 times daily.8

Pregnancy / Lactation

Avoid use. Information regarding safety and efficacy in pregnancy and lactation is lacking. Reports from Indian literature suggest the resin of B. serrata may induce abortion.8


Substrates of CYP1A2, 2C8, 2C9, 2C19, 2D6, and 3A4

Upon liquid chromatography mass spectrometry analysis, frankincense derived from B. serrata demonstrated inhibition of CYP1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. Therefore, caution is warranted when using B. serrata with medications that are substrates for these isoenzymes.2

Substrates for P-gp

Data suggest that B. serrata extract and the major boswellic acids may be potent inhibitors of P-gp via modulation of transport activity at the GI level, but not at the blood-brain barrier.73 Therefore, medications that depend on P-gp transport across the GI membrane may be impacted with coadministration of B. serrata.


According to 2 case reports, coadministration of warfarin and B. serrata may increase INR levels. The interaction may be attributed to inhibition of lipoxygenase and interference with COX-1 by B. serrata. In addition, B. serrata might inhibit CYP2C19, 3A4, and 2C9, which are involved in the metabolism of warfarin. Use of B. serrata in patients receiving warfarin is not recommended.74

Adverse Reactions

B. serrata is mostly well tolerated. It has been associated with mild GI disturbances such as nausea, abdominal pain, diarrhea, loss of appetite, and acid reflux.8, 75, 76, 77 Hepatotoxic effects were reported in a study of mice.17 A case report describes development of contact dermatitis in a 28-year-old woman who used a naturopathic cream containing B. serrata for treatment of second-degree burn. Topical and systemic corticosteroids were needed to manage her contact dermatitis, which included a local cutaneous reaction with development of bullae. A patch test produced positive results when B. serrata was tested. Months later, the patient developed contact dermatitis on her hands after applying the same cream on her husband.6


The median lethal dose (LD50) of B. serrata has been determined to be greater than 2 g/kg.3, 7, 40, 78 In rats, the acute oral LD50 of Aflapin, a synergistic composition derived from B. serrata gum resin, was 5 g/kg, and the acute dermal LD50 of Aflapin was 2 g/kg.79 A combination product containing B. serrata, Zingiber officinale, C. longa, and W. somnifera was not associated with any toxicity in rats given one dose of 10 g/kg.80



This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

1. Ghazanfar S. Handbook of Arabian Medicinal Plants. Boca Raton, FL: CRC Press; 1994:62.
2. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A. 2006;1112(1-2):255-262.16364338
3. Boswellia serrata. Altern Med Rev. 2008;13(2):165-167.18590352
4. Broadhurst C, et al. Herbal chemistry. Herbs for Health. 1998;Jan/Feb:20.
5. Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. 2011;73(3):255-261.22457547
6. Acebo E, Ratón JA, Sautúa S, Eizaguirre X, Trébol I, Pérez JL. Allergic contact dermatitis from Boswellia serrata extract in a naturopathic cream. Contact Dermatitis. 2004;51(2):91-92.15373853
7. Khan MA, Ali R, Parveen R, Najmi AK, Ahmad S. Pharmacological evidences for cytotoxic and antitumor properties of Boswellic acids from Boswellia serrata. J Ethnopharmacol. 2016;191:315-323.27346540
8. Basch E, Boon H, Davies-Heerema T, et al. Boswellia: an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother. 2004;4(3):63-83.15829470
9. Triantafyllidi A, Xanthos T, Papalois A, Triantafillidis JK. Herbal and plant therapy in patients with inflammatory bowel disease. Ann Gastroenterol. 2015;28(2):210-220.25830661
10. Bruneton J. Pharmacognosy, Phytochemistry, Medicinal Plants. Paris, France: Lavoisier Pub; 1995:607-608.
11. Al-Yasiry AR, Kiczorowska B. Frankincense – therapeutic properties. Postepy Hig Med Dosw (Online). 2016;70:380-391.27117114
12. Liu JJ, Nilsson A, Oredsson S, Badmaev V, Zhao WZ, Duan RD. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis. 2002;23(12):2087-2093.12507932
13. Xia L, Chen D, Han R, Fang Q, Waxman S, Jing Y. Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. Mol Cancer Ther. 2005;4(3):381-388.15767547
14. Park YS, Lee JH, Bondar J, Harwalkar JA, Safayhi H, Golubic M. Cytotoxic action of acetyl-11-keto-beta-boswellic acid (AKBA) on meningioma cells. Planta Med. 2002;68(5):397-401.12058313
15. Yadav VR, Prasad S, Sung B, et al. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive, and angiogenic biomarkers. Int J Cancer. 2012;130(9):2176-2184.21702037
16. Hostanska K, Daum G, Saller R. Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro. Anticancer Res. 2002;22(5):2853-2862.12530009
17. Kirste S, Treier M, Wehrle SJ, et al. Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: A prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer. 2011;117(16):3788-3795.21287538
18. Flavin DF. A lipoxygenase inhibitor in breast cancer brain metastases. J Neurooncol. 2007;82(1):91-93.17001517
19. Janssen G, Bode U, Breu H, Dohrn B, Englebrecht V, Göbel U. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr. 2000;212(4):189-195.10994549
20. Streffer JR, Bitzer M, Schabet M, Dichgans J, Weller M. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. Neurology. 2001;56(9):1219-1221.11342692
21. Azemi ME, Namjoyan F, Khodayar MJ, Ahmadpour F, Darvish Padok A, Panahi M. The antioxidant capacity and anti-diabetic effect of Boswellia serrata triana and planch aqueous extract in fertile female diabetic rats and the possible effects of reproduction and histological changes in the liver and kidneys. Jundishapur J Nat Pharm Prod. 2012;7(4):168-175.24624177
22. Shehata AM, Quintanilla-Fend L, Bettio S, Singh CB, Ammon HP. Prevention of multiple low-dose streptozotocin (MLD-STZ) diabetes in mice by an extract from gum resin of Boswellia serrata (BE). Phytomedicine. 2011;18(12):1037-1044.21831620
23. Mehrzadi S, Tavakolifar B, Huseini HF, Mosavat SH, Heydari M. The efficacy of Boswellia serrata gum resin for control of lipid profile and blood glucose in diabetic patients. Iran J Med Sci. 2016;41(3):S66.27516696
24. Schrott E, Laufer S, Lämmerhofer M, Ammon HP. Extract from gum resin of Boswellia serrata decreases IA(2)-antibody in a patient with "Late onset Autoimmune Diabetes of the Adult" (LADA). Phytomedicine. 2014;21(6):786.24698440
25. Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995;47(6):1212-1216.7603462
26. Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions. 1986;18(3-4):407-412.3751752
27. Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of anti-inflammatory actions of curcumine and boswellic acids. J Ethnopharmacol. 1993;38(2-3):113-119.8510458
28. Ammon HP, Mack T, Singh GB, Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethaolic extract of the gum resin exudate of Boswellia serrata. Planta Med. 1991;57(3):203-207.1654575
29. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992;261(3):1143-1146.1602379
30. Kiela PR, Midura AJ, Kuscuoglu N, et al. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol. 2005;288(4):G798-G808.15539433
31. Singh S, Khajuria A, Taneja SC, et al. The gastric ulcer protective effect of boswellic acids, a leukotriene inhibitor from Boswellia serrata, in rats. Phytomedicine. 2008;15(6-7):408-415.18424019
32. Hartmann RM, Fillmann HS, Martins MI, Meurer L, Marroni NP. Boswellia serrata has beneficial anti-inflammatory and antioxidant properties in a model of experimental colitis. Phytother Res. 2014;28(9):1392-1398.24619538
33. Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2(1):37-43.9049593
34. Pellegrini L, Milano E, Franceschi F, et al. Managing ulcerative colitis in remission phase: usefulness of Casperome, an innovative lecithin-based delivery system of Boswellia serrata extract. Eur Rev Med Pharmacol Sci. 2016;20(12):2695-2700.27383325
35. Rahimi R, Nikfar S, Abdollahi M. Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis. World J Gastroenterol. 2013;19(34):5738-5749.24039370
36. Chande N, MacDonald JK, McDonald JW. Interventions for treating microscopic colitis: A Cochrane inflammatory bowel disease and function bowel disorders review group systematic review of randomized trials. Am J Gastroenterol. 2009;104(1):235-241.19098875
37. Madisch A, Miehlke S, Eichele O, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis. 2007;22(12):1445-1451.17764013
38. Chande N, McDonald JW, MacDonald JK. Interventions for treating collagenous colitis. Cochrane Database Syst Rev. 2008;(2):CD003575.18425892
39. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol (German). 2001;39(1):11-17.11215357
40. Holtmeier W, Zeuzem S, Preiss J, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis. 2011;17(2):573-582.20848527
41. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2001;67(5):391-395.11488449
42. Khosravi Samani M, Mahmoodian H, Moghadamnia A, Poorsattar Bejeh Mir A, Chitsazan M. The effect of Frankincense in the treatment of moderate plaque-induced gingivitis: a double blinded randomized clinical trial. Daru. 2011;19(4):288-294.22615671
43. Prabhavathi K, Chandra US, Soanker R, Rani PU. A randomized, double blind, placebo controlled, cross over study to evaluate the analgesic activity of Boswellia serrata in healthy volunteers using mechanical pain model. Indian J Pharmacol. 2014;46(5):475-479.25298573
44. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014;(5):CD002947.24848732
45. Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardnan B. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol. 1991;33(1-2):91-95.1943180
46. Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee—a randomized double blind placebo controlled trial. Phytomedicine. 2003;10(1):3-7.12622457
47. Sontakke S, Thawani V, Pimpalkhute S, Kabra P, Babhulkar S, Hingorani L. Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian J Pharmacol. 2007;39:27-29.
48. Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8(7):615-622.22022214
49. Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85.18667054
50. Franceschi F, Togni S, Belcaro G, et al. A novel lecithin based delivery form of Boswellic acids (Casperome) for the management of osteo-muscular pain: A registry study in young rugby players. Eur Rev Med Pharmacol Sci. 2016;20(19):4156-4161.27775780
51. Etzel R. Special extract of Boswellia serrata (H 15) in the treatment of rheumatoid arthritis. Phytomedicine. 1996;3(1):91-94.23194870
52. Lampl C, Haider B, Schweiger C. Long-term efficacy of Boswellia serrata in four patients with chronic cluster headache. Cephalalgia. 2012;32(9):719-722.22767962
53. Raja AF, Ali F, Khan IA, Shawl AS, Arora DS. Acetyl-11-keto-β-boswellic acid (AKBA); targeting oral cavity pathogens. BMC Res Notes. 2011;4:406.21992439
54. Schmidt TJ, Kaiser M, Brun R. Complete structural assignment of serratol, a cembrane-type diterpene from Boswellia serrata, and evaluation of its antiprotozoal activity. Planta Med. 2011;77(8):849-850.21157686
55. Sadhasivam S, Palanivel S, Ghosh S. Synergistic antimicrobial activity of Boswellia serrata Roxb. ex Colebr. (Burseraceae) essential oil with various azoles against pathogens associated with skin, scalp and nail infections. Lett Appl Microbiol. 2016;63(6):495-501.27730658
56. Badria FA, Mohammed EA, El-Badrawy MK, El-Desouky M. Natural leukotriene inhibitor from Boswellia: A potential new alternative for treating bronchial asthma. Altern Complement Ther. 2004;10:257-265.
57. Clark CE, Arnold E, Lasserson TJ, Wu T. Herbal interventions for chronic asthma in adults and children: a systematic review and meta-analysis. Prim Care Respir J. 2010;19(4):307-314.20640388
58. Gupta I, Gupta V, Parihar A, et al. Effects of Boswellia serrata gum resin in patient with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. 1998;3(11):511-514.9810030
59. Calzavara-Pinton P, Zane C, Facchinetti E, Capezzera R, Pedretti A. Topical boswellic acids for treatment of photoaged skin. Dermatol Ther. 2010;23(suppl 1):S28-S32.20136919
60. Pedretti A, Capezzera R, Zane C, Facchinetti E, Calzavara-Pinton P. Effects of topical boswellic acid on photo and age-damaged skin: clinical, biophysical, and echographic evaluations in a double-blind, randomized, split-face study. Planta Med. 2010;76(6):555-560.19918712
61. Togni S, Maramaldi G, Bonetta A, Giacomelli L, Di Pierro F. Clinical evaluation of safety and efficacy of Boswellia-based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trial. Eur Rev Med Pharmacol Sci. 2015;19(8):1338-1344.25967706
62. Togni S, Maramaldi G, Di Pierro F, Biondi M. A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis. Clin Cosmet Investig Dermatol. 2014;7:321-327.25419153
63. Pungle P, Banavalikar M, Suthar A, Biyani M, Mengi S. Immunomodulatory activity of boswellic acids of Boswellia serrata Roxb. Indian J Exp Biol. 2003;41(12):1460-1462.15320503
64. Kapil A, Moza N. Anticomplementary activity of boswellic acids—an inhibitor of C3-convertase of the classical complement pathway. Int J Immunopharmacol. 1992;14(7):1139-1143.1452399
65. Barrett JT. Textbook of Immunology. 4th ed. St Louis, MO: CV Mosby Company; 1983:177.
66. Mahmoud MF, Diaai AA, Ahmed F. Evaluation of the efficacy of ginger, Arabic gum, and Boswellia in acute and chronic renal failure. Ren Fail. 2012;34(1):73-82.22017619
67. Moreillon JJ, Bowden RG, Deike E, et al. The use of an anti-inflammatory supplement in patients with chronic kidney disease. J Complement Integr Med. 2013;10.23828329
68. Arkalgud Rangaswamy P, Sultana A, Rahman K, Nagapattinam S. Efficacy of Boswellia serrata L. and Cyperus scariosus L. plus pelvic floor muscle training in stress incontinence in women of reproductive age. Complement Ther Clin Pract. 2014;20(4):230-236.25225151
69. Galeone G, Spadavecchia R, Balducci MT, Pagliarulo V. The role of Proxelan in the treatment of chronic prostatitis. Results of a randomized trial. Minerva Urol Nefrol (Italian). 2012;64(2):135-141.22617307
70. Wang M, Chen M, Ding Y, et al. Pretreatment with β-boswellic acid improves blood stasis induced endothelial dysfunction: role of eNOS activation. Sci Rep. 2015;5:15357.26482008
71. Dahmen U, Gu YL, Dirsch O, et al. Boswellic acid, a potent antiinflammatory drug, inhibits rejection to the same extent as high dose steroids. Transplant Proc. 2001;33(1-2):539-541.11266947
72. Sterk V, Büchele B, Simmet T. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. Planta Med. 2004;70(12):1155-1160.15643550
73. Weber CC, Reising K, Müller WE, Schubert-Zsilavecz M, Abdel-Tawab M. Modulation of Pgp function by boswellic acids. Planta Med. 2006;72(6):507-513.16773534
74. Milić N, Milosević N, Golocorbin Kon S, Bozić T, Abenavoli L, Borrelli F. Warfarin interactions with medicinal herbs. Nat Prod Commun. 2014;9(8):1211-1216.25233607
75. Gummi Boswellii. In: WHO Monographs on Selected Medicinal Plants. Vol. 4. Geneva, Switzerland: World Health Organization; 2009:48-60.
76. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: An overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet. 2011;50(6):349-369.21553931
77. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006;72(12):1100-1116.17024588
78. Singh GB, Bani S, Singh S. Toxicity and safety evaluation of boswellic acids. Phytomedicine. 1996;3(1):87-90.23194869
79. Krishnaraju AV, Sundararaju D, Vamsikrishna U, et al. Safety and toxicological evaluation of Aflapin: A novel Boswellia-derived anti-inflammatory product. Toxicol Mech Methods. 2010;20(9):556-563.20874664
80. Dey D, Chaskar S, Athavale N, Chitre D. Acute and chronic toxicity, cytochrome P450 enzyme inhibition, and hERG channel blockade studies with a polyherbal, ayurvedic formulation for inflammation. Biomed Res Int. 2015;2015:971982.25893199
81. Majeed M, Majeed S, Narayanan NK, Nagabhushanam K. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019;35(5):1457-1468.30838706

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.